Drug Trial Radar · NCT03038035
The Alzheimer's Disease THErapy With NEuroaid (ATHENE) Study
Last checked: Nov 19, 2026Latest source record: Jan 31, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
150
Planned (sponsor's estimate)
Start
Dec 2016
Primary completion
Jun 2018
Study completion Jun 2019
Sponsor
- Lead sponsor
- National University Hospital, SingaporeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 31, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
MLC601 (Neuroaid) is a Traditional Chinese Medicine (TCM) having neuroprotective and neuroproliferative properties in cellular and animal models of brain injury. It contains 9 herbal and 5 non-herbal components. MLC901 (Neuroaid II), a simplified formula of MLC601, containing only the 9 herbal components yet showing the same efficacy has become available. This study is carried out to find out if NEUROAID II (MLC901) is safe to be taken together with other established medicines for Alzheimer's disease and whether NEUROAID II (MLC901) helps in slowing down the Alzheimer's disease progression. This study will be a 6-month randomized, double-blind, placebo-controlled trial, followed by an open extension study in which all subjects who completed the main 6 month trial (irrespective of treatment allocation) will be offered open-labelled MLC901 for another 6 months.
Conditions
- Alzheimer Disease
Interventions
MLC901Drug
24 weeks intervention with orally MLC901. 2 capsules 3 times a day
PlaceboDrug
24 weeks intervention with orally placebo. 2 capsules 3 times a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluating the safety of MLC901 when it is given in combination with the standard treatment.The safety will be evaluated by adverse events, vital signs, ECG and laboratory tests, physical and neurological examinations at 6 months.Time frame: week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National University Hospital
Singapore, Singapore, Singapore · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.